Work Disability and the Cost-effectiveness of Drugs to Treat Rheumatic Diseases - Time for a New Dialogue?

J Rheumatol. 2018 Aug;45(8):1075-1077. doi: 10.3899/jrheum.180197. Epub 2018 Aug 1.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Arthritis, Psoriatic*
  • Biological Products*
  • Cost-Benefit Analysis
  • Humans
  • Rheumatic Diseases*
  • Synthetic Drugs

Substances

  • Biological Products
  • Synthetic Drugs